Shanghai Henlius Biotech, Inc. (02696) said the company has recently entered into a binding term sheet with Accord Healthcare Inc. (Accord). The company has agreed to grant a licence to Accord to develop and commercialise HLX02 trastuzumab injection (EU trade name: Zercepac) in the USA and Canada.
HLX02 trastuzumab injection is a monoclonal antibody biosimilar independently developed by the company in accordance with the guidelines for biosimilar in the PRC and the European Union for the treatment of HER2-positive early breast cancer, HER2-positive metastatic breast cancer and HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction.
etnet榮獲HKEX Awards 2023 「最佳表現證券數據供應商」大獎► 了解詳情
